From Standard-of-Care Injectables to Next-Generation S1P Receptor Modulators, Newer Treatments Offer Patients Options
Jeffrey Dunn, MD, Professor of Clinical Neurology and Chief of Neuroimmunology, Neurology at Stanford University
Advertisement
Articles by Jeffrey Dunn, MD, Professor of Clinical Neurology and Chief of Neuroimmunology, Neurology at Stanford University
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Preliminary Phase 2 Data Support Therapeutic Development of Synaptic Regenerative Drug SPG302 in ALS
2
Dental Caries and Periodontal Disease Increase Ischemic Stroke Risk, Study Shows
3
Therapeutic Promise and Mechanism of DYNE-101 to Treat Myotonic Dystrophy: Doug Kerr, MD, PhD
4
FDA Issues Complete Response Letter for Spinocerebellar Ataxia Agent Troriluzole
5
